Proposed mechanisms of GLP-1RA-induced acute pancreatitis include pancreatic duct gland hyperplasia, pancreatic ductal obstruction leading to proinflammatory reactions, acinar cell hypertrophy, and pancreatic vascular injury.36 Additionally, another mechanism seen with the use of these drugs could be the increased risk of gallbladder or biliary diseases, especially when used in higher doses, for longer periods of time, and for weight loss.37 Previous animal studies suggested a risk of acute pancreatitis after GLP-1RA-based treatment.38 In addition, an initial analysis of the Food and Drug Administration's (FDA) adverse event reporting databases suggested an increased risk for acute pancreatitis with GLP-1RA-based therapy.39 It is important to note that this type of data analysis may not be the ideal method for comparing adverse event rates between medications
We have access to Semaglutide and Tirzepatide from a compounding pharmacy for on-going use
Trends Immunol 36(2):92101
Check with your local state licensing board to see if this counts toward your CE requirement for relicensure
Model selection was based on deviance, and lambda 1se was applied as regularization criterion
Pharmacy replacement ensures treatment reliability